Clofarabine

被引：72

作者：

Pui, CH ^{[1
]}

Jeha, S ^{[1
]}

Kirkpatrick, P ^{[1
]}

机构：

[1] St Jude Childrens Res Hosp, Memphis, TN 38105 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2005年 / 4卷 / 05期

关键词：

D O I：

10.1038/nrd1724

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Clofarabine (Clolar; Genzyme), a purine nucleoside antimetabolite, was granted accelerated approval by the FDA for the treatment of paediatric patients with relapsed or refractory acute lymphoblastic leukaemia in December 2004. It is the first new drug for paediatric leukaemia to be approved in more than a decade, and the only one to receive approval for paediatric use before adult use.

引用

收藏

页码：369 / 370

页数：2

相关论文

共 18 条

[1] A phase 2 evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy. [J].

Burnett, AK ;

Russell, N ;

Kell, JW ;

Milligan, D ;

Culligan, D .

BLOOD, 2004, 104 (11) :248A-248A

[2] ORAL ANTILYMPHOCYTE ACTIVITY AND INDUCTION OF APOPTOSIS BY 2-CHLORO-2'-ARABINO-FLUORO-2'-DEOXYADENOSINE [J].

CARSON, DA ;

WASSON, DB ;

ESPARZA, LM ;

CARRERA, CJ ;

KIPPS, TJ ;

COTTAM, HB .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (07) :2970-2974

[3] Epigenetics in human disease and prospects for epigenetic therapy [J].

Egger, G ;

Liang, GN ;

Aparicio, A ;

Jones, PA .

NATURE, 2004, 429 (6990) :457-463

[4] Clofarabine plus cytarabine (ARA-C) combination is active in newly diagnosed patients (pts) ≥ age 50 with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). [J].

Faderl, S ;

Gandhi, V ;

Verstovsek, S ;

Cortes, J ;

Ravandi-Kashani, F ;

Beran, M ;

Garcia-Manero, G ;

Koller, C ;

O'Brien, S ;

Ferrajoli, A ;

Estrov, Z ;

Kwari, M ;

Plunkett, W ;

Kantarjian, HM .

BLOOD, 2004, 104 (11) :250A-250A

[5] Phase I study of clofarabine plus Idarubicin and Clofarabine plus Idarubicin plus Cytarabine (ARA-C) in patients (PTS) with relapsed and primary refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloid blast phase of chronic myeloid leukemia (CML). [J].

Faderl, S ;

Ferrajolil, A ;

Wierda, W ;

Verstovsek, S ;

Ravandi-Kashani, F ;

Garcia-Manero, G ;

Estey, E ;

Thomas, DA ;

Kornblau, S ;

Kwari, M ;

Gandhi, V ;

Kantarjian, HM .

BLOOD, 2004, 104 (11) :501A-501A

[6] Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias [J].

Faderl, S ;

Gandhi, V ;

O'Brien, S ;

Bonate, P ;

Cortes, J ;

Estey, E ;

Beran, M ;

Wierda, W ;

Garcia-Manero, G ;

Ferrajoli, A ;

Estrov, Z ;

Giles, FJ ;

Du, M ;

Kwari, M ;

Keating, M ;

Plunkett, W ;

Kantarjian, H .

BLOOD, 2005, 105 (03) :940-947

[7]

FADERL S, 2005, CANC RES 0331, DOI DOI 10.1002/CNCR.21005

[8]

*FDA, 2004, FDA LAB INF

[9] Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia [J].

Jeha, S ;

Gandhi, V ;

Chan, KW ;

McDonald, L ;

Ramirez, I ;

Madden, R ;

Rytting, M ;

Brandt, M ;

Keating, M ;

Plunkett, W ;

Kantarjian, H .

BLOOD, 2004, 103 (03) :784-789

[10] Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia [J].

Kantarjian, H ;

Gandhi, V ;

Cortes, J ;

Verstovsek, S ;

Du, M ;

Garcia-Manero, G ;

Giles, F ;

Faderl, S ;

O'Brien, S ;

Jeha, S ;

Davis, J ;

Shaked, Z ;

Craig, A ;

Keating, M ;

Plunkett, W ;

Freireich, EJ .

BLOOD, 2003, 102 (07) :2379-2386